Amiel J L, Rouessé J, Droz J P, Caille P, Travagli J P, Théodore C, Le Chevalier T, Ducret J P, Bidart M, Garnier H S
Presse Med. 1984 Jun 16;13(25):1555-7.
The results obtained with N-methyl-hydroxy-elliptinium acetate (NMHE) in the treatment of 22 assessable adult patients with metastatic renal cancer are reported. According to the WHO criteria, there were 10 responses, including 7 stabilizations, 2 partial remissions (greater than 50%) and one complete and durable remission. Since there is no other effective medical treatment for this type of tumour, and since the protocol used so far appears to have low toxicity and makes it possible to evaluate the value of the drug within 4 to 6 weeks, the trial will be extended in order to determine more precisely (+/- 5%) the degree of effectiveness of NMHE.
报告了用醋酸 N-甲基-羟基椭圆玫瑰树碱（NMHE）治疗 22 例可评估的转移性肾癌成年患者所取得的结果。根据世界卫生组织的标准，有 10 例有反应，包括 7 例病情稳定、2 例部分缓解（超过 50%）和 1 例完全且持久缓解。由于对于这类肿瘤尚无其他有效的药物治疗，而且迄今所使用的方案似乎毒性较低，并且能够在 4 至 6 周内评估该药物的价值，因此将扩大试验以更精确地（±5%）确定 NMHE 的有效性程度。
